RIVASTIGMINE
Generic: RIVASTIGMINE
Zydus Pharmaceuticals USA Inc.Manufacturer
TRANSDERMALRoute
RIVASTIGMINEActive Substance
2019-03-04Original Approval
RIVASTIGMINE is FDA application ANDA206318, sponsored by ZYDUS PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2017-03-06
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, BachupCross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules
Class II2015-08-03
Rivastigmine Tartrate Capsules, USP 1.5 mg, 60 count bottle, Rx Only, Mfd. By Dr. Reddy's Laboratories Limited, BachupalFailed Dissolution Specifications
Top Reported Reactions
1
HALLUCINATION
946 reports
2
FALL
907 reports
3
DEATH
714 reports
4
CONFUSIONAL STATE
650 reports
5
DRUG INEFFECTIVE
614 reports
6
PARKINSON^S DISEASE
419 reports
7
FATIGUE
414 reports
8
CONDITION AGGRAVATED
412 reports
9
GAIT DISTURBANCE
401 reports
10
OFF LABEL USE
382 reports